CLARIFY Trial: Improved Prostate Cancer Outcomes with PSMA PET and Personalized Treatment

Jeffrey Karnes, MD, and Geoffrey Johnson, MD, PhD, both of Mayo Clinic, continue their discussion on the CLARIFY trial, focusing on the broader implications of PSMA PET imaging for personalized treatment in prostate cancer. They explore how advanced imaging can identify distant metastases and how personalized treatment strategies, like oligometastatic interventions, might change long-term outcomes for patients. The conversation also touches on how PSMA PET scans could eventually replace or complement current surveillance methods for managing high-risk disease.